Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma

被引：0
|
作者：
Castelli, Roberto [1 ]
Gallipoli, Paolo [2 ]
Gidaro, Antonio [3 ]
Maddalena, Wu [1 ]
Arquati, Massimo [3 ]
Deliliers, Giorgio Lambertenghi [4 ]
机构：
[1] Univ Milan, Luigi Sacco Hosp Milan, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[2] Univ Cambridge, Cambridge, England
[3] Univ Milan, Luigi Sacco Hosp Milan, ADept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[4] Fdn Matarelli, Milan, Italy
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
    Lentzsch, Suzanne
    Quach, Hang
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Thiyagarajah, Piruntha
    Amin, Himal
    Casneuf, Tineke
    Sonneveld, Pieter
    Schecter, Jordan
    Hungria, Vania T. M.
    [J]. BLOOD, 2017, 130
  • [42] Bortezomib and Dexamethasone as Maintenance therapy in Relapse/Refractory multiple myeloma Patients.
    Benevolo, Giulia
    Larocca, Alessandra
    Pregno, Patrizia
    Gay, Francesca
    Botto, Barbara
    Orsucci, Lorella
    Evangelista, Andrea
    Palumbo, Antonio
    Vitolo, Umberto
    Boccadoro, Mario
    [J]. BLOOD, 2008, 112 (11) : 956 - 956
  • [43] Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    Berenson, JR
    Jagannath, S
    Barlogie, B
    Siegel, DT
    Alexanian, R
    Richardson, PG
    Irwin, D
    Alsina, M
    Rajkumar, SV
    Srkalovic, G
    Singhal, S
    Limentani, S
    Niesvizky, R
    Esseltine, DL
    Trehu, E
    Schenkein, DP
    Anderson, K
    [J]. CANCER, 2005, 104 (10) : 2141 - 2148
  • [44] BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Tsirigotis, P.
    Girkas, K. G.
    Giannopoulou, V.
    Chondropoulos, S.
    Ioannidou, E.
    Papaxoinis, G.
    Pappa, V.
    Vasilatou, D.
    Dimoula, K.
    Kapodistrias, N.
    Papageorgiou, E.
    Economopoulos, T.
    Dervenoulas, J.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 436 - 436
  • [45] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    [J]. International Journal of Hematology, 2018, 107 : 460 - 467
  • [46] ASSOCIATION OF BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Saltarelli, F.
    Veggia, B.
    Moscetti, A.
    Ferrari, A.
    Tatarelli, C.
    Conte, E.
    Cox, M. C.
    Spiriti, M. A. Aloe
    Porrini, R.
    Albanesi, M.
    Mendicino, F.
    Monarca, B.
    La Verde, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 543 - 543
  • [47] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    [J]. BLOOD, 2018, 132 (24) : 2546 - 2554
  • [48] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [49] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    [J]. CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
  • [50] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
12345